January 2017 – GCP Realises Its Investment In Fishawack, A Leading Medical Communications Group
GCP Realises Its Investment In Fishawack, A Leading Medical Communications Group
Fishawack is one of the largest independent global medical communications groups. With offices in the USA (Philadelphia and San Francisco), UK (Manchester, Oxford and Brighton), Switzerland (Basel) and a team in India (Hyderabad), Fishawack employs over 240 people, mostly PhDs, pharmacists and ex-industry personnel. Working with 15 of the top 20 pharma companies as well as innovative biotech companies, Fishawack supports medical affairs and marketing teams in educating physicians about how to optimise patient outcomes.
GCP completed the successful sale of Fishawack Group Limited, to Lloyds Development Capital on Friday 20th January, having originally invested in March 2013.
During the first 18 months of the GCP investment three bolt on acquisitions were supported and funded in Switzerland (Archimed), USA (JK Associates) and UK (Facilitate).
Following the integration of these three strategic businesses and strong organic growth across the top 20 pharma clients, the earnings of the group more than doubled.
With this increased scale, an opportune time arose to realise value for Fund III whilst supporting the management objective of continuing a larger buy and build programme.
Garrett Curran, Managing Partner at GCP, said:
“We are delighted to have worked with the Fishawack management team over the last 4 years and, after supporting three strategic acquisitions, to see the group more than double in size. We wish the team all the best for the future as they move to the next stage of their growth strategy and build scale across the impressive international group.”